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Rationale: Infections caused by influenza viruses lead to morbidity and mortality in humans and 
especially in patients with COPD. To reduce this risk, COPD patients are routinely offered an influenza 
vaccination. Response to this vaccination is well defined by the EMEA (The European Agency for the 
Evaluation of Medicinal Products, 1997). A four-fold rise in hemagglutination inhibition (HI) antibody 
titer is considered to be sufficient and a successful response to vaccination. With the influenza 
vaccination, the proportion of subjects with a significant increase in antibody titer was greater than 
40% in the general population (Fluvirin, official FDA information). Kositanont found in a poorly defined 
COPD population a protection rate of only 22% for H1N1 and 29% for H3N2. We wanted to investigate 
the response to the annual influenza vaccination in a well defined cohort of COPD patients. 
 
Methods: Within our patient population a cohort study was of well defined COPD patients with mainly 
stage II and III COPD was initiated (the COMIC study). At stable state, an influenza vaccination was 
offered and blood was obtained prior to and 4-6 weeks after vaccination. We measured the HI 
antibody titers to the influenza A strains in the vaccine. 
 
Results: In 369 COPD patients (see table 1 for baseline characteristics) the proportion of subjects with 
a fourfold increase in HI antibody titer was 3%, and with a two-fold increase 18%. Table 2 shows the 
frequency table for vaccination response. 
 
Conclusions: In a cohort of well defined COPD patients an adequate antibody response to the 
influenza vaccination was present in only 3% which is rather low and not consistent with earlier 
studies. A two-fold rise was found in 18% of the patients. The protection offered by this limited two-fold 
response is currently unclear and should be investigated. 
 
 
 
 
